Propanc Biopharma Inc (PPCB) Stock Price, Quote & News

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9882 0780

Fax: 61 3 9882 9969

Website: www.propanc.com

Address:

302, 6 Butler Street, Camberwell, Australia

IR_propancbiopharma Aug. 24 at 8:17 PM

Propanc’s recent preclinical data provides a strong scientific foundation for the next stage of PRP’s development. In advanced pancreatic cancer models, PRP achieved >90%, mean tumor growth inhibition, reduced metastatic burden, and extended median overall survival by more than 2.5x versus controls. PRP is designed to target cancer stem cells and reverse EMT, processes associated with resistance, recurrence, and metastasis. These findings do not replace human clinical evidence. They provide the rationale for generating it. With preparations for the First-In-Human Phase 1b study advancing, PRP is approaching the point where its scientific potential can begin to be evaluated in patients. $PPCB

0 · Reply

URANIUM77 Aug. 24 at 7:17 PM

$PPCB Target $15 Mcap $2.5 M Share buyback $5 M Float 2.28M 🚀🚀🔥🔥🔥🔥🔥

0 · Reply

URANIUM77 Aug. 24 at 4:39 PM

$PPCB Management believes the stock is extremely underpriced, so they are buying back $5 million of their own shares. IS THIS A CRAZY SHORT SQUEEZE CANDIDATE? Onconetix Acquisition Target Realbotix Is this a good buy now float 3.95M $ONCO The company has over 11x today's mcap in cash $ONCO The company now has $35 million in cash Mcap 2.523 million Management believes the stock is extremely underpriced, hence repurchasing own shares $5 million$PPCB Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models This must be a cheap stock now $PPCB Propanc Biopharma Initiates $5.0 Million Share Repurchase Program Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program Mcap only 2.531M Float 2.28M

0 · Reply

URANIUM77 Aug. 24 at 3:26 PM

$SLS What do you think about this one? Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models This must be a cheap stock now $PPCB Propanc Biopharma Initiates $5.0 Million Share Repurchase Program Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program Mcap only 2.531M Float 2.28M

4 · Reply

URANIUM77 Aug. 23 at 9:40 PM

$PPCB Amazing news

0 · Reply

IR_propancbiopharma Aug. 21 at 5:09 PM

$PPCB The First-In-Human study is designed to move PRP into clinical evaluation in up to 40 patients with advanced solid tumors. The study will follow two stages: · Part A will focus on dose escalation to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics while identifying recommended doses for further evaluation. · Part B will expand selected doses into one or more tumor-specific cohorts to further assess safety, tolerability, and preliminary antitumor activity. This is how promising science begins its transition into clinical evidence: by establishing how a treatment behaves in patients and building the data needed to guide its next stage of development.

0 · Reply

MoneyMacG Aug. 20 at 6:39 PM

$PPCB $PAPL $YDKG $FCHL $FRSX online

0 · Reply

URANIUM77 Aug. 20 at 4:50 PM

$PPCB Free money on the street Pick it up and Hold

0 · Reply

IR_propancbiopharma Aug. 20 at 3:48 PM

Propanc has begun finalizing the clinical trial protocol and will conduct a feasibility assessment for its planned First-In-Human Phase 1b study of PRP in up to 40 patients with advanced solid tumors. Led by Avance Clinical, the process will include protocol finalization, review of supporting clinical documents, and feedback from investigators at trial centers across Australia ahead of the planned Q4 Clinical Trial Application. Each of these steps moves PRP closer to the clinic and turns years of scientific and development work into a defined clinical pathway. For Propanc, this represents more than preparation. It is execution toward one of the Company's most important milestones: bringing PRP into human clinical development. $PPCB

0 · Reply

Joebeemer Aug. 19 at 9:01 PM

$PPCB I bought in at $2.X a month ago when volume was on scanners everywhere. Then dropped like a cinderblock sent out the side of a hot air balloon all the way down to here @$1.14. I could average down or just stay out. Idk what to do. This tire just won't hold air

0 · Reply

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Aug 18, 2026, 8:30 AM EDT - 6 days ago

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

2026-08-17T09:24:22.000Z - 7 days ago

Propanc highlights PRP as potential therapy against RAS-driven cancers

Aug 12, 2026, 8:30 AM EDT - 12 days ago

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

2026-08-06T13:51:23.000Z - 18 days ago

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Aug 5, 2026, 8:30 AM EDT - 19 days ago

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Jul 21, 2026, 8:30 AM EDT - 4 weeks ago

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

2026-07-17T21:35:21.000Z - 5 weeks ago

Propanc Biopharma registers to sell 2.5M shares of common stock for holders

2026-07-07T13:06:21.000Z - 6 weeks ago

Propanc Biopharma signs MOU with Avance Clinical for PRP clinical trial

Jul 7, 2026, 8:30 AM EDT - 6 weeks ago

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

2026-07-02T12:55:35.000Z - 7 weeks ago

Propanc Biopharma initiates share repurchase program

Jul 2, 2026, 8:30 AM EDT - 7 weeks ago

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

2026-06-16T13:41:11.000Z - 2 months ago

Propanc CEO visits European manufacturer ahead of drug production plan

Jun 16, 2026, 8:45 AM EDT - 2 months ago

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

2026-06-11T13:14:59.000Z - 2 months ago

Propanc Biopharma announces $5M share repurchase program

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Jun 2, 2026, 5:30 AM EDT - 2 months ago

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

May 20, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

2026-05-19T13:16:34.000Z - 3 months ago

Propanc Biopharma engages European CDMO for GMP production of PRP

May 19, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

2026-05-15T23:51:01.000Z - 3 months ago

Propanc Biopharma Inc trading halted, news pending

May 15, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

2026-05-14T09:34:08.000Z - 3 months ago

Propanc Biopharma announces 1-for-25 reverse stock split

May 13, 2026, 10:00 PM EDT - 3 months ago

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

2026-04-10T21:35:15.000Z - 4 months ago

Propanc Biopharma files to sell 15M shares of common stock for holders

2026-03-24T13:11:19.000Z - 5 months ago

Propanc Biopharma signs multi-year collaboration with Spanish universities

Mar 24, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

2026-03-12T13:04:12.000Z - 5 months ago

Propanc Biopharma announces highlights of PRP

Mar 12, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

2026-03-10T12:51:18.000Z - 5 months ago

Propanc Biopharma executes service agreement with FyoniBio

Mar 10, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

2026-03-03T13:59:37.000Z - 6 months ago

Propanc Biopharma highlights potential of lead asset PRP

Mar 3, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

2026-02-18T13:50:25.000Z - 6 months ago

Propanc Biopharma provides corporate update

Feb 18, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

2026-02-05T13:50:26.000Z - 7 months ago

Propanc Biopharma highlights potential of lead proenzyme therapy

Feb 5, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

2026-02-02T22:35:25.000Z - 7 months ago

Propanc Biopharma files to sell 7M shares of common stock for holders

Jan 27, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 20, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 15, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 13, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Provides Shareholder Update

Dec 22, 2025, 7:00 AM EST - 8 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 4, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 1, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Nov 17, 2025, 8:45 AM EST - 10 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 10, 2025, 8:45 AM EST - 10 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 4, 2025, 7:00 AM EST - 10 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Oct 15, 2025, 5:45 PM EDT - 11 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 11 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 7, 2025, 8:45 AM EDT - 11 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Sep 17, 2025, 8:45 AM EDT - 1 year ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 2, 2025, 9:00 AM EDT - 1 year ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Aug 19, 2025, 8:30 AM EDT - 1 year ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 14, 2025, 11:00 PM EDT - 1 year ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

IR_propancbiopharma Aug. 24 at 8:17 PM

0 · Reply

URANIUM77 Aug. 24 at 7:17 PM

$PPCB Target $15 Mcap $2.5 M Share buyback $5 M Float 2.28M 🚀🚀🔥🔥🔥🔥🔥

0 · Reply

URANIUM77 Aug. 24 at 4:39 PM

0 · Reply

URANIUM77 Aug. 24 at 3:26 PM

4 · Reply

URANIUM77 Aug. 23 at 9:40 PM

$PPCB Amazing news

0 · Reply

IR_propancbiopharma Aug. 21 at 5:09 PM

0 · Reply

MoneyMacG Aug. 20 at 6:39 PM

$PPCB $PAPL $YDKG $FCHL $FRSX online

0 · Reply

URANIUM77 Aug. 20 at 4:50 PM

$PPCB Free money on the street Pick it up and Hold

0 · Reply

IR_propancbiopharma Aug. 20 at 3:48 PM

0 · Reply

Joebeemer Aug. 19 at 9:01 PM

0 · Reply

ShangVXO Aug. 19 at 9:18 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $PPCB and $PMAX looks ready

1 · Reply

IR_propancbiopharma Aug. 18 at 5:20 PM

Understanding how each part of a clinical development program fits together makes company milestones much easier to interpret. $PPCB

0 · Reply

MrTicker Aug. 18 at 12:31 PM

$PPCB Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRPAvance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia GLOBENEWSWIRE 7:30 AM ET 8/18/2026

0 · Reply

Casualtradess Aug. 17 at 10:31 PM

$PPCB Has a High insider ownership may provide alignment..

0 · Reply

Casualtradess Aug. 17 at 10:30 PM

$PPCB 💰 Tiny market cap = potentially huge upside if clinical news is positive!!

0 · Reply

Casualtradess Aug. 17 at 10:26 PM

$PPCB why dip?

1 · Reply

IR_propancbiopharma Aug. 17 at 4:29 PM

Clinical development involves much more than preparing for a trial. Scientific, manufacturing, regulatory, and technical work all contribute to building the program. $PPCB

0 · Reply

URANIUM77 Aug. 14 at 7:07 PM

$HTZ $ADVB $PPCB $STKH $DFNS Don't forget the $5 million share buyback. Management believes the value is $20 per share. $PPCB

1 · Reply

URANIUM77 Aug. 14 at 6:50 PM

$PPCB Free money on the street now Pick it up and Hold strong

0 · Reply

_Adulis_SignalTrades_ Aug. 14 at 4:49 PM

$ADVB $DFNS $HTZ $PPCB Closed out $STKH for 63% profit. Keeping the rest which are highly shorted and holding strong. Added AMIX today. The orange peel in chief is going to do something crazy over the weekend again to manipulate markets and get shorts margin called.

1 · Reply

IR_propancbiopharma Aug. 14 at 4:00 PM

$PPCB Long before an investigational treatment can be evaluated in a First-In-Human clinical study, multiple areas of work contribute to building the foundation for clinical development. Scientific validation, clinical planning, manufacturing preparation, regulatory preparation, and bioanalytical development each play a distinct role in this process. Over the coming weeks, we'll explore each of these areas, explaining why they matter and highlighting the publicly communicated milestones that have contributed to the development of PRP. Behind every clinical development program is a company executing across multiple scientific, technical, and operational disciplines. Understanding how these areas work together provides broader context for the milestones that support the development of PRP. $PPCB

0 · Reply

IR_propancbiopharma Aug. 13 at 10:30 PM

While emerging RAS-targeted therapies focus on inhibiting oncogenic signaling, Propanc's PRP is designed to operate differently: promoting cancer cell differentiation, reversing EMT, and targeting cancer stem cells associated with recurrence, resistance, and metastasis. PRP is not mutation-specific, potentially positioning its non-cytotoxic, proenzyme-based mechanism as a complementary approach for aggressive solid tumors. Recent preclinical PDAC data showed >90% mean tumor growth inhibition, reduced metastatic burden, and >2.5x extension of median overall survival versus controls. Now, the focus moves to clinical execution. Propanc expects to file its Clinical Trial Application for the planned Phase 1b study in Q4 2026. The next step: bringing PRP into the clinic. $PPCB

0 · Reply

Market Cap	155,000.00
Revenue (ttm)	0.00
Net Income (ttm)	-1.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	489,547
Avg Vol	2,732
Day's Range	N/A - N/A
Shares Out	19,000.00
Stochastic %K	94%
Beta	2.78
Analysts	Strong Buy
Price Target	$12.50